Epigenomic networking in drug development: From pathogenic mechanisms to pharmacogenomics

Drug Development Research

Volumn 75, Issue 6, 2014, Pages 348-365

  Cacabelos, Ramõn ^a,b  

^a CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^b Centro de Investigacion Biomedica EuroEspes   (Spain)

Author keywords

DNA methyltransferase inhibitors; epigenetic drugs; epigenetics; histone acetyltransferase activators; histone deacetylase (HDAC) inhibitors; histone demethylase inhibitors; histone methyltransferase inhibitors; miRNAs; non coding RNAs; pharmacogenetics

Indexed keywords

ACYLTRANSFERASE INHIBITOR; DNA; DNA METHYLTRANSFERASE INHIBITOR; HISTONE; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE INHIBITOR; HISTONE METHYLTRANSFERASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; OXYGENASE INHIBITOR; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ENZYME INHIBITOR; MICRORNA;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA DEMETHYLATION; DNA METABOLISM; DNA METHYLATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION REGULATION; HISTONE MODIFICATION; HUMAN; NONHUMAN; PATHOGENESIS; PHARMACOEPIGENETICS; PHARMACOGENETICS; PHARMACOGENOMICS; PROTEIN PROCESSING; REVIEW; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROCEDURES;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DRUG DESIGN; DRUG DISCOVERY; ENZYME INHIBITORS; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; MICRORNAS; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; NEURODEGENERATIVE DISEASES; PHARMACOGENETICS;

EID: 84925656065     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21219     Document Type: Review

References (98)

1. Adwan L, Zawia NH,. 2013. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. Pharmacol Ther 139: 41-50.
2. Alyea RA, Gollapudi BB, Rasoulpour RJ,. 2014. Are we ready to consider transgenerational epigenetic effects in human health risk assessment? Environ Mol Mutagen 55: 292-298.
3. Bardhan K, Liu K,. 2013. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) 5: 676-713.
4. Benyshek DC,. 2013. The "early life" origins of obesity-related health disorders: new discoveries regarding the intergenerational transmission of developmentally programmed traits in the global cardiometabolic health crisis. Am J Phys Anthropol 152 (Suppl. 57): 79-93.
5. Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, Borgo F, Moscato U, Bertini E, Mercuri E, Neri G,. 2005. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 13: 256-259.
6. Cacabelos R,. 2011. The path to personalized medicine in mental disorders. In:, Ritsner MS, editor. The handbook of neuropsychiatric biomarkers, endophenotypes and genes, Vol. 4. Dordrecht, The Netherlands, Springer, p 3-63.
7. Cacabelos R,. 2012a. Pharmacogenomics of central nervous system (CNS) drugs. Drug Dev Res 73: 461-476.
8. Cacabelos R,. 2012b. World guide for drug use and pharmacogenomics. Corunna, Spain, EuroEspes Publishing.
9. Cacabelos R,. 2012c. The metabolomics paradigm of pharmacogenomics in complex disorders. Metabolomics 2: e119. doi: 10.4172/2153-0769.1000e119.
10. Cacabelos R,. 2014. Metabolomics of epigenetic drugs: precautionary measures. Metabolomics 4: e126.doi: 10.4172/2153-0769.1000e126.
11. Cacabelos R, Martínez-Bouza R,. 2011. Genomics and pharmacogenomics of schizophrenia. CNS Neurosci Ther 17: 541-565.
12. Cacabelos R, Torrellas C,. 2014. Epigenetic drug discovery for Alzheimer's disease. Expert Opin Drug Discov 3: 1-28.
13. Cacabelos R, Cacabelos P, Aliev G,. 2013. Genomics and pharmacogenomics of antipsychotic drugs. Open J Psychiatr 3: 46-139.
14. Cacabelos R, Cacabelos P, Torrellas C, Tellado I, Carril JC,. 2014a. Pharmacogenomics of Alzheimer's disease. Novel therapeutic strategies for drug development. Methods Mol Biol. doi: 10.1007/978-1-4939-0956-8-13.
15. Cacabelos R, Torrellas C, Lõpez-Muñoz F,. 2014b. Epigenomics of Alzheimer's disease. J Exp Clin Med 6: 75e82. doi: 10.1016/j.jecm.2014.03.010.
16. Chen S, Ge X, Chen Y, Lv N, Liu Z, Yuan W,. 2013. Advances with RNA interference in Alzheimer's disease research. Drug Des Devel Ther 7: 117-125.
17. Chouliaras L, Rutten BP, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os J, Steinbusch HW, van den Hove DL,. 2010. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 90: 498-510.
18. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT,. 2009. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32: 591-601.
19. Clapier CR, Cairns BR,. 2009. The biology of chromatin remodeling complexes. Annu Rev Biochem 78: 273-304.
20. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, et al. 2013. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829.
21. Dalton VS, Kolshus E, McLoughlin DM,. 2014. Epigenetics and depression: return of the repressed. J Affect Disord 155: 1-12.
22. Dauncey MJ,. 2013. Genomic and epigenomic insights into nutrition and brain disorders. Nutrients 5: 887-914.
23. Donmez G, Wang D, Cohen DE, Guarente L,. 2010. SIRT1 suppresses-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142: 320-332.
24. Duygu B, Poels EM, da Costa Martins PA,. 2013. Genetics and epigenetics of arrhythmia and heart failure. Front Genet 4: 219. doi: 10.3389/fgene.2013.00219.
25. Ernst C, Morton CC,. 2013. Identification and function of long non-coding RNA. Front Cell Neurosci 7: 168. doi: 10.3389/fncel.2013.00168.
26. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH,. 2007. Recovery of learning and memory is associated with chromatin remodelling. Nature 447: 178-182.
27. Francis YI, Fà M, Ashraf H, Zhang H, Staniszewski A, Latchman DS, Arancio O,. 2009. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 18: 131-139.
28. Gavery MR, Roberts SB,. 2013. Predominant intragenic methylation is associated with gene expression characteristics in a bivalve mollusc. Peer J 1: e215. doi: 10.7717/peerj.215.
29. Girardot M, Feil R, Llères D,. 2013. Epigenetic deregulation of genomic imprinting in humans: causal mechanisms and clinical implications. Epigenomics 5: 715-728.
30. Govindarajan N, Rao P, Burkhardt S, Sananbenesi F, Schlüter OM, Bradke F, Lu J, Fischer A,. 2013. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med 5: 52-63.
31. Gräff J, Tsai LH,. 2013. The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol 53: 311-330.
32. Gräff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, Nieland TJ, Fass DM, Kao PF, Kahn M, et al. 2012. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483: 222-226.
33. Green MJ, Chia TY, Cairns MJ, Cairns MJ, Cairns MJ, Wu J, Tooney PA, Scott RJ, Carr VJ,; Australian Schizophrenia Research Bank. 2014. Catechol-O-methyltransferase (COMT) genotype moderates the effects of childhood trauma on cognition and symptoms in schizophrenia. J Psychiatr Res 49: 43-50.
34. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, et al. 2009. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459: 55-60.
35. Gupta S, Kim SY, Artis S, Molfese DL, Schumacher A, Sweatt JD, Paylor RE, Lubin FD,. 2010. Histone methylation regulates memory formation. J Neurosci 30: 3589-3599.
36. Hannula-Jouppi K, Muurinen M, Lipsanen-Nyman M, Reinius LE, Ezer S, Greco D, Kere J,. 2014. Differentially methylated regions in maternal and paternal uniparental disomy for chromosome 7. Epigenetics 9: 351-365.
37. Harlaar N, Bryan AD, Thayer RE, Karoly HC, Oien N, Hutchison KE,. 2014. Methylation of a CpG site near the ALDH1A2 gene is associated with loss of control over drinking and related phenotypes. Alcohol Clin Exp Res 38: 713-721.
38. Helin K, Dhanak D,. 2013. Chromatin proteins and modifications as drug targets. Nature 502: 480-488.
39. Højfeldt JW, Agger K, Helin K,. 2013. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 12: 917-930.
40. Huynh JL, Casaccia P,. 2013. Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment. Lancet Neurol 12: 195-206.
41. Ishimaru N, Fukuchi M, Hirai A, Chiba Y, Tamura T, Takahashi N, Tabuchi A, Tsuda M, Shiraishi M,. 2010. Differential epigenetic regulation of BDNF and NT-3 genes by trichostatin A and 5-aza-2′-deoxycytidine in Neuro-2a cells. Biochem Biophys Res Commun 394: 173-177.
42. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, et al. 2004. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640.
43. Itzykson R, Fenaux P,. 2014. Epigenetics of myelodysplastic syndromes. Leukemia 28: 497-506.
44. Jiao AL, Slack FJ,. 2014. RNA-mediated gene activation. Epigenetics 9: 27-36.
45. Julien C, Tremblay C, Émond V,. 2009. SIRT1 decrease parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68: 48-58.
46. Kelly TK, De Carvalho DD, Jones PA,. 2010. Epigenetic modifications as therapeutic targets. Nat Biotechnol 28: 1069-1078.
47. Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, Sutherland K, Armstrong R, Weng WK, Showe LC, Wysocka M, et al. 2012. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol 87: 354-360.
48. Kiguchi N, Kobayashi Y, Saika F, Kishioka S,. 2013. Epigenetic upregulation of CCL2 and CCL3 via histone modifications in infiltrating macrophages after peripheral nerve injury. Cytokine 64: 666-672.
49. Kim IW, Han N, Burckart GJ, Oh JM,. 2014. Epigenetic changes in gene expression for drug-metabolizing enzymes and transporters. Pharmacotherapy 34: 140-150.
50. Kim MS, Akhtar MW, Adachi M, Mahgoub M, Bassel-Duby R, Kavalali ET, Olson EN, Monteggia LM,. 2012. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J Neurosci 32: 10879-10886.
51. Konsoula Z, Barile FA,. 2012. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. J Pharmacol Toxicol Methods 66: 215-220.
52. Koshibu K, Gräff J, Beullens M, Heitz FD, Berchtold D, Russig H, Farinelli M, Bollen M, Mansuy IM,. 2009. Protein phosphatase 1 regulates the histone code for long-term memory. J Neurosci 29: 13079-13089.
53. Kubota T, Miyake K, Hirasawa T,. 2013. Role of epigenetics in Rett syndrome. Epigenomics 5: 583-592.
54. Lahiri DK, Sokol DK, Erickson C, Ray B, Ho CY, Maloney B,. 2013. Autism as early neurodevelopmental disorder: evidence for an sAPPα-mediated anabolic pathway. Front Cell Neurosci 7: 94. doi: 10.3389/fncel.2013.00094.
55. Laurent L, Wong E, Li G, Huynh T, Tsirigos A, Ong CT, Low HM, Kin Sung KW, Rigoutsos I, Loring J, et al. 2010. Dynamic changes in the human methylome during differentiation. Genome Res 20: 320-331.
56. Lee J, Hwang YJ, Kim KY,. 2013. Epigenetic mechanisms of neurodegeneration in Huntington's disease. Neurother 10: 664-676.
57. Lee J, Hwang YJ, Ryu H, Kowall NW, Ryu H,. 2014. Nucleolar dysfunction in Huntington's disease. Biochim Biophys Acta 1842: 785-790.
58. Lee YS,. 2013. Genetics of nonsyndromic obesity. Curr Opin Pediatr 25: 666-673.
59. Li G, Warden C, Zou Z, Neman J, Krueger JS, Jain A, Jandial R, Chen M,. 2013. Altered expression of polycomb group genes in glioblastoma multiforme. PLoS ONE 8: e80970. doi: 10.1371/journal.pone.0080970.
60. Li LC,. 2014. Chromatin remodeling by the small RNA machinery in mammalian cells. Epigenetics 9: 45-52.
61. Lithner CU, Hernandez CM, Nordberg A, Sweatt JD,. 2009. Epigenetic changesrelated to beta-amyloid-implications for Alzheimer's disease. Alzheimers Dement 5: P304-P304.
62. Liu R, Lei JX, Luo C, Lan X, Chi L, Deng P, Lei S, Ghribi O, Liu QY,. 2012. Increased EID1 nuclear translocation impairs synaptic plasticity and memory function associated with pathogenesis of Alzheimer's disease. Neurobiol Dis 45: 902-912.
63. Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, Cao Y,. 2013. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res 32: 96. doi: 10.1186/1756-9966-32-96.
64. Lötsch J, Schneider G, Reker D, Parnham MJ, Schneider P, Geisslinger G, Doehring A,. 2013. Common non-epigenetic drugs as epigenetic modulators. Trends Mol Med 19: 742-753.
65. Mahgoub M, Monteggia LM,. 2013. Epigenetics and psychiatry. Neurother 10: 734-741.
66. Marks PA,. 2010. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066.
67. Marks PA, Xu WS,. 2009. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107: 600-608.
68. Mbadiwe T, Millis RM,. 2013. Epigenetics and autism. Autism Res Treat 2013: 826156. doi: 10.1155/2013/826156.
69. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J,. 1997. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8: 358-368.
70. Morrison KE, Rodgers AB, Morgan CP, Bale TL,. 2014. Epigenetic mechanisms in pubertal brain maturation. Neuroscience 264: 17-24.
71. Moumné L, Betuing S, Caboche J,. 2013. Multiple aspects of gene dysregulation in Huntington's disease. Front Neurol 4: 127. doi: 10.3389/fneur.2013.00127.
72. Myung NH, Zhu X, Kruman II,. 2008. Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age (Dordr) 30: 209-215.
73. Nebbioso A, Carafa V, Benedetti R, Altucci L,. 2012. Trials with epigenetic drugs: an update. Mol Oncol 6: 657-682.
74. Ogawa O, Zhu X, Lee HG, Raina A, Obrenovich ME, Bowser R, Ghanbari HA, Castellani RJ, Perry G, Smith MA,. 2003. Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta Neuropathol 105: 524-528.
75. Peedicayil J,. 2014. Epigenetic drugs in cognitive disorders. Curr Pharm Des 20: 1840-1846.
76. Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC, Cota P, Wittnam JL, Gogol-Doering A, Opitz L, et al. 2010. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328: 753-756.
77. Philibert RA, Beach SR, Lei MK, Brody GH,. 2013. Changes in DNA methylation at the aryl hydrocarbon receptor repressor may be a new biomarker for smoking. Clin Epigenetics 5: 19. doi: 10.1186/1868-7083-5-19.
78. Rangasamy S, D'Mello SR, Narayanan V,. 2013. Epigenetics, autism spectrum, and neurodevelopmental disorders. Neurother 10: 742-756.
79. Roberts TC, Morris KV, Weinberg MS,. 2014. Perspectives on the mechanism of transcriptional regulation by long non-coding RNAs. Epigenetics 9: 13-20.
80. Rossi LE, Avila DE, Spallanzani RG, Ziblat A, Fuertes MB, Lapyckyj L, Croci DO, Rabinovich GA, Domaica CI, Zwirner NW, et al. 2012. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J Leukoc Biol 91: 321-331.
81. Ryu H, Barrup M, Kowall NW, McKee AC,. 2008. P3-260: epigenetic modification in a monozygotic twin with Alzheimer's disease. Alzheimers Dement 4: T598.
82. Salminen A, Tapiola T, Korhonen P, Suuronen T,. 1998. Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res Mol Brain Res 61: 203-206.
83. Shirazi J, Shah S, Sagar D, Nonnemacher MR, Wigdahl B, Khan ZK, Jain P,. 2013. Epigenetics, drugs of abuse, and the retroviral promoter. J Neuroimmune Pharmacol 8: 1181-1196.
84. Szulwach KE, Jin P,. 2014. Integrating DNA methylation dynamics into a framework for understanding epigenetic codes. Bioessays 36: 107-117.
85. Tabolacci E, Chiurazzi P,. 2013. Epigenetics, fragile X syndrome and transcriptional therapy. Am J Med Genet A 161: 2797-2808.
86. Tian F, Marini AM, Lipsky RH,. 2010. Effects of histone deacetylase inhibitor Trichostatin A on epigenetic changes and transcriptional activation of Bdnf promoter 1 by rat hippocampal neurons. Ann N Y Acad Sci 1199: 186-193.
87. Van den Hove DL, Kompotis K, Lardenoije R, Kenis G, Mill J, Steinbusch HW, Lesch KP, Fitzsimons CP, De Strooper B, Rutten BP,. 2014. Epigenetically regulated microRNAs in Alzheimer's disease. Neurobiol Aging 35: 731-745.
88. Varela MA, Roberts TC, Wood MJ,. 2013. Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy. Neurother 10: 621-631.
89. Venturelli S, Berger A, Weiland T, Essmann F, Waibel M, Nuebling T, Häcker S, Schenk M, Schulze-Osthoff K, Salih HR, et al. 2013. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells. Mol Cancer Ther 12: 2226-2236.
90. Verhoeven KJ, Preite V,. 2014. Epigenetic variation in asexually reproducing organisms. Evolution 68: 644-655.
91. Vogel-Ciernia A, Wood MA,. 2014. Neuron-specific chromatin remodeling: a missing link in epigenetic mechanisms underlying synaptic plasticity, memory, and intellectual disability disorders. Neuropharmacology 80: 18-27.
92. Walker MP, LaFerla FM, Oddo SS, Brewer GJ,. 2013. Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease. Age (Dordr) 35: 519-531.
93. Wang J, Yu JT, Tan MS, Tan L,. 2013. Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy. Ageing Res Rev 12: 1024-1041.
94. Wu P, Zuo X, Deng H, Liu X, Liu L, Ji A,. 2013. Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Res Bull 97: 69-80.
95. Xu K, Dai XL, Huang HC, Jiang ZF,. 2011. Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid Med Cell Longev 2011. doi: 10.1155/2011/143269.
96. Yang H, Lee SM, Gao B, Zhang J, Fang D,. 2013. The histone deacetylase Sirtuin 1 deacetylates IRF1 and programs dendritic cells to control Th17 differentiation during autoimmune inflammation. J Biol Chem 288: 37256-37266.
97. Zhang K, Schrag M, Crofton A, Trivedi R, Vinters H, Kirsch W,. 2012. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 12: 1261-1268.
98. Zhang L, Zhang Y, Chou CJ, Inks ES, Wang X, Li X, Hou J, Xu W,. 2014. Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities. ChemMedChem 9: 638-648.